Screener
BridgeBio Pharma BBIO Noncontrolling interests in subsidiaries
Noncontrolling interests in subsidiaries at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Treasury stock, at cost; 10,582,998 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025 | (533,279) | (323,276) |
| Additional paid-in capital | 2,155,318 | 2,057,646 |
| Accumulated other comprehensive income (loss) | (7) | 12 |
| Accumulated deficit | (4,137,453) | (3,821,194) |
| Total BridgeBio stockholders’ deficit | (2,515,215) | (2,086,610) |
| Noncontrolling interests | 10,340 | 10,599 |
| Total stockholders’ deficit | (2,504,875) | (2,076,011) |
| Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | $1,217,299 | $936,025 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's noncontrolling interests in subsidiaries?
- BridgeBio Pharma (BBIO) reported noncontrolling interests in subsidiaries of $10.34M in Q2 2026.
- How has BridgeBio Pharma's noncontrolling interests in subsidiaries changed year-over-year?
- BridgeBio Pharma's noncontrolling interests in subsidiaries increased by 4.6% year-over-year, from $9.89M to $10.34M.
- What is the long-term trend for BridgeBio Pharma's noncontrolling interests in subsidiaries?
- Over 5 years (2020 to 2025), BridgeBio Pharma's noncontrolling interests in subsidiaries has grown at a -26.2% compound annual growth rate (CAGR), from $48.35M to $10.6M.
- What does noncontrolling interests in subsidiaries mean?
- This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.
Ask your AI about BridgeBio Pharma's noncontrolling interests in subsidiaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude